About Epithelix
Epithelix is a company based in Plan-les-ouates (Switzerland) founded in 2006. Epithelix offers products and services including MucilAir™, SmallAir™, AlveolAir™, and Cilia-X. Epithelix operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Plan-les-ouates, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$556.46 K (USD), Grant
Jan 01, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Epithelix
Epithelix offers a comprehensive portfolio of products and services, including MucilAir™, SmallAir™, AlveolAir™, and Cilia-X.
In vitro 3D human nasal epithelium for respiratory research
In vitro 3D human small airway epithelium for testing
In vitro 3D human alveolar epithelium for health studies
Software for batch analysis of ciliary beat frequency
Funding Insights of Epithelix
Investors in Epithelix
Epithelix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Epithelix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epithelix
Investment portfolio details for Epithelix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epithelix
Detailed financials for Epithelix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epithelix Comparisons
Peer comparison for Epithelix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epithelix
Epithelix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Epithelix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epithelix
Complete news archive for Epithelix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epithelix
Epithelix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Epithelix is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Epithelix is a tissue engineering company providing in-vitro solutions for drug development and toxicity testing for the human respiratory tract. Epithelix provides RD solutions to PharmaBiotechs for the study of human respiratory diseases (asthma, COPD, cystic fibrosis, etc.) in order to reduce animal experiments. Its main product, MucilAir, is a 3-D model of the human airway epithelium made up of primary human cells isolated from the nasal cavity, trachea, and bronchus.
Epithelix's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Epithelix offers MucilAir™, SmallAir™, AlveolAir™, and Cilia-X.
Epithelix has 1 investor. Key investors include European Union.